Bir miyelodisplastik hücre hattı (P39) üzerine bortezomib ve arsenik trioksid’in etkileri: Bir gen anlatımı çalışması

Translated title of the contribution: Bortezomib and arsenic trioxide activity on a myelodysplastic cell line (P39): A gene expression study

Hakan Savlı, Sara Galimberti, Deniz Sünnetçi, Martina Canestraro, Giuseppe Palumbo, B. Nagy, Francesco di Raimondo, Mario Petrini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.

Original languageUndefined/Unknown
Pages (from-to)206-212
Number of pages7
JournalTurkish Journal of Haematology
Volume32
Issue number3
DOIs
Publication statusPublished - Aug 4 2015

Fingerprint

Myelodysplastic Syndromes
Gene Expression
Cell Line
Estradiol
BRCA2 Gene
Proteasome Inhibitors
Gene Regulatory Networks
Oligonucleotide Array Sequence Analysis
Real-Time Polymerase Chain Reaction
Down-Regulation
Genes
Bortezomib
arsenic trioxide

Keywords

  • Arsenic trioxide
  • Bortezomib
  • Gene expression
  • MDS
  • NF-κB

ASJC Scopus subject areas

  • Hematology

Cite this

Bir miyelodisplastik hücre hattı (P39) üzerine bortezomib ve arsenik trioksid’in etkileri : Bir gen anlatımı çalışması. / Savlı, Hakan; Galimberti, Sara; Sünnetçi, Deniz; Canestraro, Martina; Palumbo, Giuseppe; Nagy, B.; di Raimondo, Francesco; Petrini, Mario.

In: Turkish Journal of Haematology, Vol. 32, No. 3, 04.08.2015, p. 206-212.

Research output: Contribution to journalArticle

Savlı, H, Galimberti, S, Sünnetçi, D, Canestraro, M, Palumbo, G, Nagy, B, di Raimondo, F & Petrini, M 2015, 'Bir miyelodisplastik hücre hattı (P39) üzerine bortezomib ve arsenik trioksid’in etkileri: Bir gen anlatımı çalışması', Turkish Journal of Haematology, vol. 32, no. 3, pp. 206-212. https://doi.org/10.4274/tjh.2014.0058
Savlı, Hakan ; Galimberti, Sara ; Sünnetçi, Deniz ; Canestraro, Martina ; Palumbo, Giuseppe ; Nagy, B. ; di Raimondo, Francesco ; Petrini, Mario. / Bir miyelodisplastik hücre hattı (P39) üzerine bortezomib ve arsenik trioksid’in etkileri : Bir gen anlatımı çalışması. In: Turkish Journal of Haematology. 2015 ; Vol. 32, No. 3. pp. 206-212.
@article{cc2b50cb50a14a61b6f2f913791e7306,
title = "Bir miyelodisplastik h{\"u}cre hattı (P39) {\"u}zerine bortezomib ve arsenik trioksid’in etkileri: Bir gen anlatımı {\cc}alışması",
abstract = "Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.",
keywords = "Arsenic trioxide, Bortezomib, Gene expression, MDS, NF-κB",
author = "Hakan Savlı and Sara Galimberti and Deniz S{\"u}nnet{\cc}i and Martina Canestraro and Giuseppe Palumbo and B. Nagy and {di Raimondo}, Francesco and Mario Petrini",
year = "2015",
month = "8",
day = "4",
doi = "10.4274/tjh.2014.0058",
language = "Undefined/Unknown",
volume = "32",
pages = "206--212",
journal = "Turkish Journal of Haematology",
issn = "1300-7777",
publisher = "Aves",
number = "3",

}

TY - JOUR

T1 - Bir miyelodisplastik hücre hattı (P39) üzerine bortezomib ve arsenik trioksid’in etkileri

T2 - Bir gen anlatımı çalışması

AU - Savlı, Hakan

AU - Galimberti, Sara

AU - Sünnetçi, Deniz

AU - Canestraro, Martina

AU - Palumbo, Giuseppe

AU - Nagy, B.

AU - di Raimondo, Francesco

AU - Petrini, Mario

PY - 2015/8/4

Y1 - 2015/8/4

N2 - Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.

AB - Objective: We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39. Materials and Methods: Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR. Results: Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings. Conclusion: Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.

KW - Arsenic trioxide

KW - Bortezomib

KW - Gene expression

KW - MDS

KW - NF-κB

UR - http://www.scopus.com/inward/record.url?scp=84938496681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938496681&partnerID=8YFLogxK

U2 - 10.4274/tjh.2014.0058

DO - 10.4274/tjh.2014.0058

M3 - Article

C2 - 25913414

AN - SCOPUS:84938496681

VL - 32

SP - 206

EP - 212

JO - Turkish Journal of Haematology

JF - Turkish Journal of Haematology

SN - 1300-7777

IS - 3

ER -